Rosiglitazone increased heart failure but did not differ from metformin plus sulphonylurea for other CV outcomes at interim analysis.
SCMS-Diabetes Medical School, Newcastle upon Tyne, UK. E-philip.home@newcastle.ac.uk
P D
PD
Home
S J
SJ
Pocock
H
H
Beck-Nielsen